Emerging combination therapies to overcome resistance in EGFR-driven tumors.

  title={Emerging combination therapies to overcome resistance in EGFR-driven tumors.},
  author={Margherita Ratti and Gianluca Tomasello},
  journal={Anti-cancer drugs},
  volume={25 2},
The epidermal growth factor receptor (EGFR) is responsible for the growth and progression of tumor cells; its overexpression and deregulation of its downstream signaling pathway have been found in many different neoplasms. These characteristics make it an ideal target for cancer treatment. Two classes of EGFR inhibitors, which bind to different parts of this molecule, have been developed and studied: monoclonal antibodies, such as cetuximab and panitumumab and tyrosine kinase inhibitors… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
12 Citations
120 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 12 extracted citations


Publications referenced by this paper.
Showing 1-10 of 120 references

Drug development

  • R Dienstmann, S De Dosso, E Felip, J. Tabernero
  • 2013

The emerging role of MET/HGF inhibitors in oncology

  • GV Scagliotti, S Novello, J. von Pawel
  • Cancer Treat Rev
  • 2013

Similar Papers

Loading similar papers…